EICHORCondition: ALS · Sponsor: Shionogi
The objective of this study is to evaluate the long-term safety and tolerability of oral edaravone in subjects with Amyotrophic Lateral Sclerosis (ALS) over 24 and 48 weeks.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| St. Joseph's Hospital and Medical Center (SJHMC) - Barrow Neurological Institute (BNI) - The Gregory W. Fulton ALS and Neuromuscular Disease Center | Phoenix, Arizona, United States | — |
| Neuromuscular Research Center | Phoenix, Arizona, United States | — |
| Woodland Research Northwest | Rogers, Arkansas, United States | — |
| Sutter Health | San Francisco, California, United States | — |
| University of Colorado Anschutz Medical Campus | Aurora, Colorado, United States | — |
| UF Health Cancer Center | Gainesville, Florida, United States | — |
| Emory University - School of Medicine | Atlanta, Georgia, United States | — |
| Johns Hopkins University | Baltimore, Maryland, United States | — |
| University of Michigan - ALS Center of Excellence | Ann Arbor, Michigan, United States | — |
| University of Michigan Health System (UMHS) - Allergy Clinic - Northville Health Center Location | Northville, Michigan, United States | — |
| Essentia Institute of Rural Health | Duluth, Minnesota, United States | — |
| Neurology Associates, P.C - Lincoln | Lincoln, Nebraska, United States | — |
+ 41 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04165824